Koss-Olinger Consulting’s Pacific Biosciences PACB Stock Holding History

Koss-Olinger Consulting’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,600,000	Closed	-$4.86M	–	277
2025 Q4	$4.86M	Sell	2,600,000 -700,000	-21%	-$1.35M	0.38%	31
2025 Q3	$4.09M	Hold	3,300,000	–	–	0.34%	41
2025 Q2	$4.09M	Buy	3,300,000 +300,000	+10%	+$346K	0.34%	42
2025 Q1	$3.54M	Buy	3,000,000 +1,000,000	+50%	+$1.53M	0.3%	41
2024 Q4	$3.66M	Buy	2,000,000 +1,200,000	+150%	+$2.34M	0.32%	41
2024 Q3	$1.36M	Hold	800,000	–	–	0.12%	93
2024 Q2	$1.1M	Buy	+800,000	New	+$1.62M	0.1%	96
2024 Q1	–	Sell	-100,000	Closed	-$981K	–	220
2023 Q4	$981K	Buy	+100,000	New	+$818K	0.1%	99
2023 Q3	–	Sell	-60,000	Closed	-$798K	–	298
2023 Q2	$798K	Hold	60,000	–	–	0.09%	105
2023 Q1	$695K	Buy	+60,000	New	+$597K	0.09%	112
2021 Q3	–	Sell	-15,000	Closed	-$525K	–	263
2021 Q2	$525K	Hold	15,000	–	–	0.08%	131
2021 Q1	$500K	Buy	+15,000	New	+$525K	0.09%	126

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Koss-Olinger Consulting's PACB Position: Q1 2026 in Review

Koss-Olinger Consulting sold out of Pacific Biosciences (PACB) in Q1 2026, closing a stake of 2,600,000 shares — an estimated $4.86M sold.

Koss-Olinger Consulting first reported a position in PACB in Q1 2021 and held it in 12 quarters. The position peaked at $4.86M in Q4 2025. 231 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Koss-Olinger Consulting reported no remaining Pacific Biosciences position as of Q1 2026 after selling out during the quarter.
Koss-Olinger Consulting sold 2,600,000 Pacific Biosciences shares in Q1 2026, an estimated $4.86M.
Koss-Olinger Consulting first reported a position in Pacific Biosciences in Q1 2021 and held it in 12 quarters.
Koss-Olinger Consulting's Pacific Biosciences position peaked at $4.86M in Q4 2025.
231 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Koss-Olinger Consulting's 13F filing for Q1 2026, filed 7 May 2026.